Pharmacological Activity of Ibuprofen Release from Measoporous Silica

Y. Lang, D. Finn, A. Pandit, Pamela Walsh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Novel drug delivery systems (DDS) to improve the pharmacokinetic profile of hydrophobic drugs following oral administration are an area of keen interest in drug research. An ideal DDS should not adversely affect drug activity, be capable of delivering a therapeutic dose of drug, and allow homogenous drug loading and drug release. Mesoporous silica has been proposed for this application, with ibuprofen employed as the model drug. It was hypothesised that mesoporous silica MCM-41 is capable of delivering a pharmacologically therapeutic dose of ibuprofen. Ibuprofen-loaded MCM-41 can be prepared reproducibly at a drug to carrier ratio of 30% (wt/wt). The release profile was seen to be 90% within 2 h. Initial assessment of COX-1 inhibitory activity suggests the absence of adverse effects attributable to drug-carrier interaction. The results of this study provide further evidence in support of the proposed use of mesoporous silica in drug delivery.
Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalJournal of Materials Science: Materials in Medicine
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Ibuprofen
activity (biology)
Silicon Dioxide
drugs
Silica
Multicarrier modulation
Pharmacology
silicon dioxide
Pharmaceutical Preparations
Drug Carriers
Pharmacokinetics
Drug Delivery Systems
Drug delivery
delivery
Drug Interactions
Oral Administration
dosage
Therapeutics
profiles
Research

Cite this

@article{b8d8b32b34e449888e6186f52e812046,
title = "Pharmacological Activity of Ibuprofen Release from Measoporous Silica",
abstract = "Novel drug delivery systems (DDS) to improve the pharmacokinetic profile of hydrophobic drugs following oral administration are an area of keen interest in drug research. An ideal DDS should not adversely affect drug activity, be capable of delivering a therapeutic dose of drug, and allow homogenous drug loading and drug release. Mesoporous silica has been proposed for this application, with ibuprofen employed as the model drug. It was hypothesised that mesoporous silica MCM-41 is capable of delivering a pharmacologically therapeutic dose of ibuprofen. Ibuprofen-loaded MCM-41 can be prepared reproducibly at a drug to carrier ratio of 30{\%} (wt/wt). The release profile was seen to be 90{\%} within 2 h. Initial assessment of COX-1 inhibitory activity suggests the absence of adverse effects attributable to drug-carrier interaction. The results of this study provide further evidence in support of the proposed use of mesoporous silica in drug delivery.",
author = "Y. Lang and D. Finn and A. Pandit and Pamela Walsh",
year = "2012",
month = "1",
doi = "10.1007/s10856-011-4488-z",
language = "English",
volume = "23",
pages = "73--80",
journal = "Journal of Materials Science: Materials in Medicine",
issn = "0957-4530",
publisher = "Springer Netherlands",
number = "1",

}

Pharmacological Activity of Ibuprofen Release from Measoporous Silica. / Lang, Y.; Finn, D.; Pandit, A.; Walsh, Pamela.

In: Journal of Materials Science: Materials in Medicine, Vol. 23, No. 1, 01.2012, p. 73-80.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacological Activity of Ibuprofen Release from Measoporous Silica

AU - Lang, Y.

AU - Finn, D.

AU - Pandit, A.

AU - Walsh, Pamela

PY - 2012/1

Y1 - 2012/1

N2 - Novel drug delivery systems (DDS) to improve the pharmacokinetic profile of hydrophobic drugs following oral administration are an area of keen interest in drug research. An ideal DDS should not adversely affect drug activity, be capable of delivering a therapeutic dose of drug, and allow homogenous drug loading and drug release. Mesoporous silica has been proposed for this application, with ibuprofen employed as the model drug. It was hypothesised that mesoporous silica MCM-41 is capable of delivering a pharmacologically therapeutic dose of ibuprofen. Ibuprofen-loaded MCM-41 can be prepared reproducibly at a drug to carrier ratio of 30% (wt/wt). The release profile was seen to be 90% within 2 h. Initial assessment of COX-1 inhibitory activity suggests the absence of adverse effects attributable to drug-carrier interaction. The results of this study provide further evidence in support of the proposed use of mesoporous silica in drug delivery.

AB - Novel drug delivery systems (DDS) to improve the pharmacokinetic profile of hydrophobic drugs following oral administration are an area of keen interest in drug research. An ideal DDS should not adversely affect drug activity, be capable of delivering a therapeutic dose of drug, and allow homogenous drug loading and drug release. Mesoporous silica has been proposed for this application, with ibuprofen employed as the model drug. It was hypothesised that mesoporous silica MCM-41 is capable of delivering a pharmacologically therapeutic dose of ibuprofen. Ibuprofen-loaded MCM-41 can be prepared reproducibly at a drug to carrier ratio of 30% (wt/wt). The release profile was seen to be 90% within 2 h. Initial assessment of COX-1 inhibitory activity suggests the absence of adverse effects attributable to drug-carrier interaction. The results of this study provide further evidence in support of the proposed use of mesoporous silica in drug delivery.

U2 - 10.1007/s10856-011-4488-z

DO - 10.1007/s10856-011-4488-z

M3 - Article

VL - 23

SP - 73

EP - 80

JO - Journal of Materials Science: Materials in Medicine

JF - Journal of Materials Science: Materials in Medicine

SN - 0957-4530

IS - 1

ER -